Baird lowered the firm’s price target on Medpace (MEDP) to $358 from $362 and keeps a Neutral rating on the shares. The firm adjusted its model following Q4 results.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP: